Akari Therapeutics Plc (AKTX): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of AKTX were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
No AKTX insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
AKTX short interest
Low short interest. Less than 0.1% of AKTX shares are sold short. Over the last 12 reports the number of shares short went down 72%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 17,903 AKTX shares were sold short, 0.0% of the shares outstanding, up 2.1% from the report before. At the average daily volume of 44,456 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 17,903 | 0.00% | +2% | 44,456 | 1.0 |
| Oct 15, 2026 | 17,539 | 0.00% | +21% | 42,143 | 1.0 |
| Sep 30, 2026 | 14,529 | 0.00% | +35% | 62,368 | 1.0 |
| Sep 15, 2026 | 10,763 | 0.00% | -64% | 101,607 | 1.0 |
| Aug 31, 2026 | 30,117 | 0.00% | -20% | 84,207 | 1.0 |
| Aug 14, 2026 | 37,660 | 0.00% | +38% | 42,080 | 1.0 |
| Jul 31, 2026 | 27,299 | 0.00% | +66% | 37,573 | 1.0 |
| Jul 15, 2026 | 16,430 | 0.00% | -9% | 71,381 | 1.0 |
| Jun 30, 2026 | 17,997 | 0.00% | -60% | 121,877 | 1.0 |
| Jun 15, 2026 | 45,077 | 0.00% | -63% | 88,099 | 1.0 |
| May 29, 2026 | 121,540 | 0.00% | +88% | 4.96M | 1.0 |
| May 15, 2026 | 64,685 | 0.00% | +301% | 35,844 | 1.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Akari Therapeutics company events
Akari Therapeutics filed 12 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership, listing). The latest was on Oct 30, 2026.
- Oct 30, 2026VoteReported shareholder vote results. Filing
- Oct 1, 2026LeadershipAkari Therapeutics, Plc, entered into an amendment, to its Chief Executive Officer Agreement, dated as of March 14, 2025, with Abizer Gaslightwala, the Company’s Chief Executive Officer, which amended the CEO Agreement to provide for the following: ● an increase in Mr. Gaslightwala’s annual base… Filing
- Aug 13, 2026ResultsReleased financial results. Filing
- Jul 2, 2026VoteReported shareholder vote results. Filing
- Jun 26, 2026AgreementAs previously disclosed on its Current Report on Form 8-K on May 22, 2026, Akari Therapeutics, Plc entered into a securities purchase agreement with certain investors, pursuant to which the Company agreed to sell and issue in a private placement an aggregate of 1,470,588 unregistered American… Filing
- May 22, 2026AgreementAkari Therapeutics, Plc entered into a securities purchase agreement with certain investors, pursuant to which the Company agreed to sell and issue in a private placement an aggregate of 1,470,588 unregistered American Depository Shares, each representing 80,000 of the Company’s ordinary shares, or… Filing
- Mar 17, 2026SharesChanged the rights of its shareholders. Filing
- Mar 2, 2026VoteReported shareholder vote results. Filing
- Dec 17, 2025AgreementAnd Item 3.02 and the exhibits to this Current Report on Form 8-K. Item 1.01. Filing
- Dec 16, 2025VoteReported shareholder vote results. Filing
- Dec 8, 2025AnnouncementShared information with investors. Filing
- Nov 26, 2025ListingAkari Therapeutics, Plc was notified by the Nasdaq Listing Qualifications that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Akari Therapeutics financials
Famous investors that hold AKTX
1 of the 50 well-known investors we track reported holding AKTX in their latest 13F filing. The largest position is Ken Griffin's, worth $201K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 21,637 | $201K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named AKTX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | MMCAP International Inc. SPC | 13G/A | 0.6% |
| Nov 13, 2026 | MMCAP International Inc. SPC | 13G/A | 0.6% |
| Nov 12, 2026 | Bank of Montreal | 13G/A | 0.8% |
| Nov 12, 2026 | Bank of Montreal | 13G/A | 0.8% |
Questions about Akari Therapeutics Plc (AKTX) stock
Are AKTX insiders buying or selling?
No AKTX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in AKTX?
As of Oct 30, 2026, 17,903 AKTX shares were sold short, 0.0% of the shares outstanding, up 2.1% from the report before. At the average daily volume of 44,456 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold AKTX?
1 of the 50 well-known investors we track reported AKTX in their latest 13F filing, including Ken Griffin. The largest position is worth $201K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.